Provided by Tiger Trade Technology Pte. Ltd.

ProShares Ultra Health Care

57.82
+0.77171.35%
Post-market: 57.820.00000.00%16:15 EDT
Volume:4K
Turnover:234.97K
Market Cap:93.67M
PE:- -
High:57.82
Open:56.69
Low:56.69
Close:57.05
52wk High:64.60
52wk Low:42.76
Shares:1.62M
Float Shares:1.62M
Volume Ratio:0.17
T/O Rate:0.25%
Dividend:0.63
Dividend Rate:1.10%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Judge Rejects Pfizer, BioNTech, and Moderna Bid to Dismiss Monsanto mRNA Patent Lawsuit

Stock News
·
Sep 29

Perrigo Co. PLC Stock Underperforms Monday When Compared to Competitors

Dow Jones
·
Sep 29

Estee Lauder Cos. Cl a Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Sep 29

Sector Update: Healthcare

MT Newswires Live
·
Sep 29

Market Chatter: Eli Lilly CEO Plans Larger Deals to Target New Disease Areas

MT Newswires Live
·
Sep 29

Lilly CEO Eyes Bigger Deals in Hunt for Pharma's 'white Spaces' - Bloomberg News

Reuters
·
Sep 29

Robert Hunter to be New UnitedHealthcare President

Reuters
·
Sep 29

Eli Lilly CEO tells Bloomberg sees more deals in untapped areas

TIPRANKS
·
Sep 29

Robert Hunter in Linkedin Post Says Stepping into New Role as President of Unitedhealthcare

THOMSON REUTERS
·
Sep 29

Lawyers in Alabama's TikTok Settlement Set to Earn $14 Million

Reuters
·
Sep 29

Rexel launches €500m capital increase to fund GCG acquisition and protect leverage

TIPRANKS
·
Sep 29

Teva Pharmaceutical's Duvakitug Could be Validated by Merck's Tulisokibart Results, Oppenheimer Says

MT Newswires Live
·
Sep 28

US Drugmakers Turn to China for Licensing Deals

Reuters
·
Sep 28

Johnson & Johnson (JNJ) Gets a Buy from Scotiabank

TIPRANKS
·
Sep 28

Taking Ozempic? a Routine Eye Exam Could Help You Understand Your Risk for Vision Loss

Dow Jones
·
Sep 28

FDA Approves AbbVie’s JUVMO for Adults with Parkinson’s Disease

Reuters
·
Sep 28

U.S. FDA Approves Abbvie's Juvmo™ (Tavapadon) for Parkinson's Disease

THOMSON REUTERS
·
Sep 28

Abbvie - Juvmo Expected to be Available in the U.S. in October 2026

THOMSON REUTERS
·
Sep 28

Eli Lilly price target raised to $1,500 from $1,400 at JPMorgan

TIPRANKS
·
Sep 28

Merck in License Pact Worth up to $2.13 Billion with SciBrunch Therapeutics

Dow Jones
·
Sep 28